SEARCH

SEARCH BY CITATION

References

  • 1
    Memon AA, Tomenson JA, Bothwell J, Friedmann PS. Prevalence of solar damage and actinic keratosis in a Merseyside population. Br J Dermatol 2000; 142: 11541159.
  • 2
    Frost CA, Green AC. Epidemiology of solar keratoses. Br J Dermatol 1994; 131: 455464.
  • 3
    Harvey I, Frankel S, Marks R, Shalom D, Nolan-Farrell M. Non-melanoma skin cancer and solar keratoses II analytical results of the South Wales Skin Cancer Study. Br J Cancer 1996; 74: 13081312.
  • 4
    Bickers DR, Lim HW, Margolis D et al. The burden of skin diseases: 2004 a joint project of the American Academy of Dermatology Association and the Society for Investigative Dermatology. J Am Acad Dermatol 2006; 55: 490500.
  • 5
    Green A, Battistutta D. Incidence and determinants of skin cancer in a high-risk Australian population. Int J Cancer 1990; 46: 356361.
  • 6
    Salasche SJ. Epidemiology of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol 2000; 42: 47.
  • 7
    Bernard P, Dupuy A, Sasco A et al. Basal cell carcinomas and actinic keratoses seen in dermatological practice in France: a cross-sectional Survey. Dermatology 2008; 216: 194199.
  • 8
    Martin L, Bonerandi JJ. Carcinome épidermoïde cutané (carcinome spinocellulaire): recommandations de pratique clinique pour la prise en charge diagnostique et thérapeutique. Rapport intégral. Ann Dermatol Venereol 2009; 136: S189S242.
  • 9
    Haute AS. Guidelines for the diagnosis and treatment of cutaneous squamous cell carcinome and precursor lesions. Guidelines. Rev Stomatol Chir Maxillofac 2010; 111: 228237.
  • 10
    Bonerandi JJ, Beauvillain C, Caquant L et al. Guidelines for the diagnosis and treatment of cutaneous squamous cell carcinoma and precursor lesions. J Eur Acad Dermatol Venereol 2011; 25: 151.
  • 11
    Drake LA, Ceilley RI, Cornelison RL et al. Guidelines of care for actinic keratoses. Committee on Guidelines of Care. J Am Acad Dermatol 1995; 32: 9598.
  • 12
    de Berker D, McGregor JM, Hughes BR; British Association of Dermatologists Therapy Guidelines and Audit Subcommittee. Guidelines for the management of actinic keratoses. Br J Dermatol 2007; 156: 222230.
  • 13
    Rossi R, Calzavara-Pinton PG, Giannetti A et al. Italian guidelines and therapeutic algorithm for actinic keratoses. G Ital Dermatol Venereol 2009; 144: 713723.
  • 14
    Stockfleth E, Kerl H. Guidelines for the management of actinic keratoses. Eur J Dermatol 2006; 16: 599606.
  • 15
    Stockfleth E, Ferrandiz C, Grob JJ, Leigh I, Pehamberger H, Kerl H; European Skin Academy. Development of a treatment algorithm for actinic keratoses: a European Consensus. Eur J Dermatol 2008; 18: 651659.
  • 16
    Nashan D, Meiss F, Müller M. Therapeutic strategies for actinic keratoses – a systematic review. Eur J Dermatol 2013; 23: 1432.
  • 17
    Lansbury L, Leonardi-Bee J, Perkins W, Goodacre T, Tweed JA, Bath-Hextall FJ. Interventions for non-metastatic squamous cell carcinoma of the skin. Cochrane Database Syst Rev 2010; CD007869.
  • 18
    Gupta AK, Inniss K, Wainwright R, Chow M, Cooper E. Interventions for actinic keratoses (Protocol). Cochrane Database Syst Rev 2003; CD004415.
  • 19
    Ackerman AB, Mones JM. Solar (actinic) keratosis is squamous cell carcinoma. Br J Dermatol 2006; 155: 922.
  • 20
    Marks R, Foley P, Goodman G, Hage BH, Selwood TS. Spontaneous clearance of solar keratoses: the case for conservative management. Br J Dermatol 1986; 115: 649655.
  • 21
    Frost C, Williams G, Green A. High incidence and regression rates of solar keratoses in a Queensland community. J Invest Dermatol 2000; 115: 273277.
  • 22
    Dodson JM, DeSpain J, Hewett JE, Clark DP. Malignant potential of actinic keratoses and the controversy over treatment. A patient-oriented perspective. Arch Dermatol 1991; 127: 10291031.
  • 23
    Feldman SR, Fleischer AB Jr. Progression of actinic keratosis to squamous cell carcinoma revisited: clinical and treatment implications. Cutis 2011; 87: 201207.
  • 24
    Marks R, Rennie G, Selwood TS. Malignant transformation of solar keratoses to squamous carcinoma. Lancet 1988; 1: 795797.
  • 25
    Mittelbronn MA, Mullins DL, Ramos-Caro FA, Flowers FP. Frequency of pre-existing actinic keratosis in cutaneous squamous cell carcinoma. Int J Dermatol 1998; 37: 677681.
  • 26
    Marks R, Rennie G, Selwood T. The relationship of basal cell carcinomas and squamous cell carcinomas to solar keratoses. Arch Dermatol 1988; 124: 10391042.
  • 27
    Kanjilal S, Strom SS, Clayman GL et al. p53 mutations in nonmelanoma skin cancer of the head and neck: molecular evidence for field cancerization. Cancer Res 1995; 55: 36043609.
  • 28
    Szeimies RM, Torezan L, Niwa A et al. Clinical, histopathological and immunohistochemical assessment of human skin field cancerization before and after photodynamic therapy. Br J Dermatol 2012; 167: 150159.
  • 29
    Quaedvlieg PJ, Tirsi E, Thissen MR, Krekels GA. Actinic keratosis. How to differentiate the good and the bad ones? Eur J Dermatol 2006; 16: 335339.
  • 30
    Krawtchenko N, Roewert-Huber J, Ulrich M, Mann I, Sterry W, Stockfleth E. A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up. Br J Dermatol 2007; 157: 3440.
  • 31
    Freeman M, Vinciullo C, Francis D et al. A comparison of photodynamic therapy using topical methyl aminolevulinate (Metvix) with single cycle cryotherapy in patients with actinic keratosis: a prospective, randomized study. J Dermatolog Treat 2003; 14: 99106.
  • 32
    Szeimies RM, Karrer S, Radakovic-Fijan S et al. Photodynamic therapy using topical methyl 5-aminolevulinate compared with cryotherapy for actinic keratosis: a prospective, randomized study. J Am Acad Dermatol 2002; 47: 258262.
  • 33
    Morton C, Campbell S, Gupta G et al. Intraindividual, right-left comparison of topical methyl aminolaevulinate-photodynamic therapy and cryotherapy in subjects with actinic keratoses: a multicentre, randomized controlled study. Br J Dermatol 2006; 155: 10291036.
  • 34
    Kaufmann R, Spelman L, Weightman W et al. Multicentre intraindividual randomized trial of topical methyl aminolaevulinate-photodynamic therapy vs. cryotherapy for multiple actinic keratoses on the extremities. Br J Dermatol 2008; 158: 994999.
  • 35
    Prens SP, Vries KD, Neumann HA, Prens EP. Non-ablative fractional resurfacing in combination with topical tretinoin cream as a field treatment modality for multiple actinic keratosis: a pilot study and review of other field treatment modalities. J Dermatolog Treat 2013; 24: 227231.
  • 36
    Torgsverd-Bo K, Haak CS, Thaysen-Petersen D, Wulf HC, Anderson RR, Haedesdal M. Intensified photodynamic therapy of actinic keratoses with fractional CO2 laser: a randomized clinical trial. Br J Dermatol 2012; 166: 12621269.
  • 37
    Katz TM, Goldberg LH, Marquez D et al. Nonablative fractional photothermolysis for facial actinic keratoses: 6 month follow-up with histologic evaluation. J Am Acad Dermatol 2011; 65: 349356.
  • 38
    Résumé des caractéristiques du produit, Metvixia®, VIDAL 2012.
  • 39
    Braathen LR, Morton CA, Basset-Seguin N et al. Photodynamic therapy for skin field cancerization: an international consensus. International Society for Photodynamic Therapy in Dermatology. J Eur Acad Dermatol Venereol 2012; 26: 10631066.
  • 40
    Morton CA, Szeimies RM, Sidoroff A, Braathen LR. European guidelines for topical photodynamic therapy part 1: treatment delivery and current indications – actinic keratoses, Bowen's disease, basal cell carcinoma. J Eur Acad Dermatol Venereol 2013; 27: 536544.
  • 41
    Pariser D, Loss R, Jarratt M et al. Topical methyl-aminolevulinate photodynamic therapy using red light-emitting diode light for treatment of multiple actinic keratoses: a randomized, double-blind, placebo-controlled study. J Am Acad Dermatol 2008; 59: 569576.
  • 42
    Pariser DM, Lowe NJ, Stewart DM et al. Photodynamic therapy with topical methyl aminolevulinate for actinickeratosis: results of a prospective randomized multicenter trial. J Am Acad Dermatol 2003; 48: 227232.
  • 43
    Braathen LR, Paredes BE, Saksela O et al. Short incubation with methyl aminolevulinate for photodynamic therapy of actinic keratoses. J Eur Acad Dermatol Venereol 2009; 23: 550555.
  • 44
    Wiegell SR, Wulf HC, Szeimies RM et al. Daylight photodynamic therapy for actinic keratosis: an international consensus: International Society for Photodynamic Therapy in Dermatology. J Eur Acad Dermatol Venereol 2012; 26: 673679.
  • 45
    Olsen EA, Abernethy ML, Kulp-Shorten C et al. A double-blind, vehicle-controlled study evaluating masoprocol cream in the treatment of actinic keratoses on the head and neck. J Am Acad Dermatol 1991; 24: 738743.
  • 46
    Rivers JK, Arlette J, Shear N, Guenther L, Carey W, Poulin Y. Topical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluronan gel. Br J Dermatol 2002; 146: 94100.
  • 47
    Stege H. Effect of xenogenic repair enzymes on photoimmunology and photocarcinogenesis. J Photochem Photobiol, B 2001; 65: 105108.
  • 48
    Résumé des caractéristiques du produit, Efudix®, VIDAL 2012.
  • 49
    Tanghetti E, Werschler P. Comparison of 5% 5-fluorouracil cream and 5% imiquimod cream in the management of actinic keratoses on the face and scalp. J Drugs Dermatol 2007; 6: 144147.
  • 50
    Loven K, Stein L, Furst K, Levy S. Evaluation of the efficacy and tolerability of 0.5% fluorouracil cream and 5% fluorouracil cream applied to each side of the face in patients with actinic keratosis. Clin Ther 2002; 24: 9901000.
  • 51
    Résumé des caractéristiques du produit, Aldara®, VIDAL 2012.
  • 52
    Jorizzo JL, Markowitz O, Lebwohl MG et al. A randomized, double-blinded, placebo-controlled, multicenter, efficacy and safety study of 3.75% imiquimod cream following cryosurgery for the treatment of actinic keratoses. J Drugs Dermatol 2010; 9: 11011108.
  • 53
    Lebwohl M, Dinehart S, Whiting D et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. J Am Acad Dermatol 2004; 50: 714721.
  • 54
    Szeimies RM, Gerritsen MJ, Gupta G et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histology. J Am Acad Dermatol 2004; 51: 547555.
  • 55
    Korman N, Moy R, Ling M et al. Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials. Arch Dermatol 2005; 141: 467473.
  • 56
    Jorizzo J, Dinehart S, Matheson R et al. Vehicle-controlled, doubled-blind, randomized study of imiquimod 5% cream applied 3 days per week in one or two courses of treatment for actinic keratoses on the head. J Am Acad Dermatol 2007; 57: 265268.
  • 57
    Alomar A, Bichel J, McRae S. Vehicle-controlled, randomized, double-blind study to assess safety and efficacy of imiquimod 5% cream applied once daily 3 days per week in one or two courses of treatment of actinic keratoses on the head. Br J Dermatol 2007; 157: 133141.
  • 58
    Résumé des caractéristiques du produit, Solaraze®, VIDAL 2012.
  • 59
    Wolf JE Jr, Taylor JR, Tschen E, Kang S. Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses. Int J Dermatol 2001; 40: 709713.
  • 60
    Résumé des caractéristiques du produit, Picato®, extract from EPAR 29 November 2012 (EMA Website).
  • 61
    Lebwohl M, Swanson N, Anderson LL, Melgaard A, Xu Z, Berman B. Ingenol mebutate for actinic keratoses. N Engl J Med 2012; 366: 10101019.
  • 62
    O'Reilly Zwald F, Brown M. Skin cancer in solid organ transplant recipients: advances in therapy and management. Part I. Epidemiology of skin cancer in solid organ transplant recipients. J Am Acad Dermatol 2011; 65: 253261.
  • 63
    O'Reilly Zwald F, Brown M. Skin cancer in solid organ transplant recipients: advances in therapy and management. Part II. Management of skin cancer in solid organ transplant recipients. J Am Acad Dermatol 2011; 65: 263279.
  • 64
    Robinson JK, Turrisi R, Mallett KA et al. Efficacy of an educational intervention with kidney transplant recipients to promote skin self-examination for squamous cell carcinoma detection. Arch Dermatol 2011; 147: 689695.
  • 65
    Uhlenhake EE. Optimal treatment of actinic keratoses. Clin Interv Aging 2013; 8: 2935.
  • 66
    Ceilley RI, Jorizzo JL. Current issues in the management of actinic keratosis. J Am Acad Dermatol 2013; 68: S28S38.
  • 67
    Ulrich C, Jürgensen JS, Degen A et al. Prevention of non-melanoma skin cancer in organ transplant patients by regular use of a sunscreen: a 24 months, prospective, case-control study. Br J Dermatol 2009; 161: 7884.
  • 68
    Sambandan DR, Ratner D. Sunscreens: an overview and update. J Am Acad Dermatol 2011; 64: 748758.